Chronic low back pain (CLBP), defined as continuous low back pain lasting for at least three months, represents the largest segment of the chronic pain therapy market. Prescription treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs), opioid-based analgesics, antiepileptic drugs, and cytokine inhibitors. Although prescription drug-treatment rates in this population are relatively high, opportunity exists for more-potent yet safe therapies. This content provides quantitative insight into U.S. and European primary care physicians’ perceptions of the key treatment drivers and goals in the management of CLBP, the existing level of unmet need in this indication, and the remaining commercial opportunities.
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. PCPs and 31 European GPs fielded in January 2020.
Key companies: Bristol-Myers Squibb, Horizon Therapeutics, Janssen, Pfizer, Purdue
Key drugs: Celecoxib, Duexis (ibuprofen / famotidine), fentanyl transdermal patch, oxycodone CR, pregabalin, tramadol ER, triamcinolone (injectable)